La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

Identifieur interne : 001119 ( Ncbi/Curation ); précédent : 001118; suivant : 001120

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

Auteurs : I. H. Richard ; M. P. Mcdermott ; R. Kurlan ; J. M. Lyness ; P. G. Como ; N. Pearson ; S. A. Factor ; J. Juncos ; C. Serrano Ramos ; M. Brodsky ; C. Manning ; L. Marsh ; L. Shulman ; H. H. Fernandez ; K. J. Black ; M. Panisset ; C. W. Christine ; W. Jiang ; C. Singer ; S. Horn ; R. Pfeiffer ; D. Rottenberg ; J. Slevin ; L. Elmer ; D. Press ; H. C. Hyson ; W. Mcdonald

Source :

RBID : PMC:3324323

Abstract

Objective:

To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD).

Methods:

A total of 115 subjects with PD were enrolled at 20 sites. Subjects were randomized to receive an SSRI (paroxetine; n = 42), an SNRI (venlafaxine extended release [XR]; n = 34), or placebo (n = 39). Subjects met DSM-IV criteria for a depressive disorder, or operationally defined subsyndromal depression, and scored >12 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D). Subjects were followed for 12 weeks (6-week dosage adjustment, 6-week maintenance). Maximum daily dosages were 40 mg for paroxetine and 225 mg for venlafaxine XR. The primary outcome measure was change in the HAM-D score from baseline to week 12.

Results:

Treatment effects (relative to placebo), expressed as mean 12-week reductions in HAM-D score, were 6.2 points (97.5% confidence interval [CI] 2.2 to 10.3, p = 0.0007) in the paroxetine group and 4.2 points (97.5% CI 0.1 to 8.4, p = 0.02) in the venlafaxine XR group. No treatment effects were seen on motor function.

Conclusions:

Both paroxetine and venlafaxine XR significantly improved depression in subjects with PD. Both medications were generally safe and well tolerated and did not worsen motor function.

Classification of Evidence:

This study provides Class I evidence that paroxetine and venlafaxine XR are effective in treating depression in patients with PD.


Url:
DOI: 10.1212/WNL.0b013e3182516244
PubMed: 22496199
PubMed Central: 3324323

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:3324323

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease</title>
<author>
<name sortKey="Richard, I H" sort="Richard, I H" uniqKey="Richard I" first="I. H." last="Richard">I. H. Richard</name>
</author>
<author>
<name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M. P." last="Mcdermott">M. P. Mcdermott</name>
</author>
<author>
<name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name>
</author>
<author>
<name sortKey="Lyness, J M" sort="Lyness, J M" uniqKey="Lyness J" first="J. M." last="Lyness">J. M. Lyness</name>
</author>
<author>
<name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P. G." last="Como">P. G. Como</name>
</author>
<author>
<name sortKey="Pearson, N" sort="Pearson, N" uniqKey="Pearson N" first="N." last="Pearson">N. Pearson</name>
</author>
<author>
<name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name>
</author>
<author>
<name sortKey="Juncos, J" sort="Juncos, J" uniqKey="Juncos J" first="J." last="Juncos">J. Juncos</name>
</author>
<author>
<name sortKey="Serrano Ramos, C" sort="Serrano Ramos, C" uniqKey="Serrano Ramos C" first="C." last="Serrano Ramos">C. Serrano Ramos</name>
</author>
<author>
<name sortKey="Brodsky, M" sort="Brodsky, M" uniqKey="Brodsky M" first="M." last="Brodsky">M. Brodsky</name>
</author>
<author>
<name sortKey="Manning, C" sort="Manning, C" uniqKey="Manning C" first="C." last="Manning">C. Manning</name>
</author>
<author>
<name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L." last="Marsh">L. Marsh</name>
</author>
<author>
<name sortKey="Shulman, L" sort="Shulman, L" uniqKey="Shulman L" first="L." last="Shulman">L. Shulman</name>
</author>
<author>
<name sortKey="Fernandez, H H" sort="Fernandez, H H" uniqKey="Fernandez H" first="H. H." last="Fernandez">H. H. Fernandez</name>
</author>
<author>
<name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K. J." last="Black">K. J. Black</name>
</author>
<author>
<name sortKey="Panisset, M" sort="Panisset, M" uniqKey="Panisset M" first="M." last="Panisset">M. Panisset</name>
</author>
<author>
<name sortKey="Christine, C W" sort="Christine, C W" uniqKey="Christine C" first="C. W." last="Christine">C. W. Christine</name>
</author>
<author>
<name sortKey="Jiang, W" sort="Jiang, W" uniqKey="Jiang W" first="W." last="Jiang">W. Jiang</name>
</author>
<author>
<name sortKey="Singer, C" sort="Singer, C" uniqKey="Singer C" first="C." last="Singer">C. Singer</name>
</author>
<author>
<name sortKey="Horn, S" sort="Horn, S" uniqKey="Horn S" first="S." last="Horn">S. Horn</name>
</author>
<author>
<name sortKey="Pfeiffer, R" sort="Pfeiffer, R" uniqKey="Pfeiffer R" first="R." last="Pfeiffer">R. Pfeiffer</name>
</author>
<author>
<name sortKey="Rottenberg, D" sort="Rottenberg, D" uniqKey="Rottenberg D" first="D." last="Rottenberg">D. Rottenberg</name>
</author>
<author>
<name sortKey="Slevin, J" sort="Slevin, J" uniqKey="Slevin J" first="J." last="Slevin">J. Slevin</name>
</author>
<author>
<name sortKey="Elmer, L" sort="Elmer, L" uniqKey="Elmer L" first="L." last="Elmer">L. Elmer</name>
</author>
<author>
<name sortKey="Press, D" sort="Press, D" uniqKey="Press D" first="D." last="Press">D. Press</name>
</author>
<author>
<name sortKey="Hyson, H C" sort="Hyson, H C" uniqKey="Hyson H" first="H. C." last="Hyson">H. C. Hyson</name>
</author>
<author>
<name sortKey="Mcdonald, W" sort="Mcdonald, W" uniqKey="Mcdonald W" first="W." last="Mcdonald">W. Mcdonald</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">22496199</idno>
<idno type="pmc">3324323</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324323</idno>
<idno type="RBID">PMC:3324323</idno>
<idno type="doi">10.1212/WNL.0b013e3182516244</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000630</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000630</idno>
<idno type="wicri:Area/Pmc/Curation">000630</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000630</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000868</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000868</idno>
<idno type="wicri:Area/Ncbi/Merge">001119</idno>
<idno type="wicri:Area/Ncbi/Curation">001119</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease</title>
<author>
<name sortKey="Richard, I H" sort="Richard, I H" uniqKey="Richard I" first="I. H." last="Richard">I. H. Richard</name>
</author>
<author>
<name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M. P." last="Mcdermott">M. P. Mcdermott</name>
</author>
<author>
<name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name>
</author>
<author>
<name sortKey="Lyness, J M" sort="Lyness, J M" uniqKey="Lyness J" first="J. M." last="Lyness">J. M. Lyness</name>
</author>
<author>
<name sortKey="Como, P G" sort="Como, P G" uniqKey="Como P" first="P. G." last="Como">P. G. Como</name>
</author>
<author>
<name sortKey="Pearson, N" sort="Pearson, N" uniqKey="Pearson N" first="N." last="Pearson">N. Pearson</name>
</author>
<author>
<name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name>
</author>
<author>
<name sortKey="Juncos, J" sort="Juncos, J" uniqKey="Juncos J" first="J." last="Juncos">J. Juncos</name>
</author>
<author>
<name sortKey="Serrano Ramos, C" sort="Serrano Ramos, C" uniqKey="Serrano Ramos C" first="C." last="Serrano Ramos">C. Serrano Ramos</name>
</author>
<author>
<name sortKey="Brodsky, M" sort="Brodsky, M" uniqKey="Brodsky M" first="M." last="Brodsky">M. Brodsky</name>
</author>
<author>
<name sortKey="Manning, C" sort="Manning, C" uniqKey="Manning C" first="C." last="Manning">C. Manning</name>
</author>
<author>
<name sortKey="Marsh, L" sort="Marsh, L" uniqKey="Marsh L" first="L." last="Marsh">L. Marsh</name>
</author>
<author>
<name sortKey="Shulman, L" sort="Shulman, L" uniqKey="Shulman L" first="L." last="Shulman">L. Shulman</name>
</author>
<author>
<name sortKey="Fernandez, H H" sort="Fernandez, H H" uniqKey="Fernandez H" first="H. H." last="Fernandez">H. H. Fernandez</name>
</author>
<author>
<name sortKey="Black, K J" sort="Black, K J" uniqKey="Black K" first="K. J." last="Black">K. J. Black</name>
</author>
<author>
<name sortKey="Panisset, M" sort="Panisset, M" uniqKey="Panisset M" first="M." last="Panisset">M. Panisset</name>
</author>
<author>
<name sortKey="Christine, C W" sort="Christine, C W" uniqKey="Christine C" first="C. W." last="Christine">C. W. Christine</name>
</author>
<author>
<name sortKey="Jiang, W" sort="Jiang, W" uniqKey="Jiang W" first="W." last="Jiang">W. Jiang</name>
</author>
<author>
<name sortKey="Singer, C" sort="Singer, C" uniqKey="Singer C" first="C." last="Singer">C. Singer</name>
</author>
<author>
<name sortKey="Horn, S" sort="Horn, S" uniqKey="Horn S" first="S." last="Horn">S. Horn</name>
</author>
<author>
<name sortKey="Pfeiffer, R" sort="Pfeiffer, R" uniqKey="Pfeiffer R" first="R." last="Pfeiffer">R. Pfeiffer</name>
</author>
<author>
<name sortKey="Rottenberg, D" sort="Rottenberg, D" uniqKey="Rottenberg D" first="D." last="Rottenberg">D. Rottenberg</name>
</author>
<author>
<name sortKey="Slevin, J" sort="Slevin, J" uniqKey="Slevin J" first="J." last="Slevin">J. Slevin</name>
</author>
<author>
<name sortKey="Elmer, L" sort="Elmer, L" uniqKey="Elmer L" first="L." last="Elmer">L. Elmer</name>
</author>
<author>
<name sortKey="Press, D" sort="Press, D" uniqKey="Press D" first="D." last="Press">D. Press</name>
</author>
<author>
<name sortKey="Hyson, H C" sort="Hyson, H C" uniqKey="Hyson H" first="H. C." last="Hyson">H. C. Hyson</name>
</author>
<author>
<name sortKey="Mcdonald, W" sort="Mcdonald, W" uniqKey="Mcdonald W" first="W." last="Mcdonald">W. Mcdonald</name>
</author>
</analytic>
<series>
<title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<idno type="eISSN">1526-632X</idno>
<imprint>
<date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Objective:</title>
<p>To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD).</p>
</sec>
<sec>
<title>Methods:</title>
<p>A total of 115 subjects with PD were enrolled at 20 sites. Subjects were randomized to receive an SSRI (paroxetine; n = 42), an SNRI (venlafaxine extended release [XR]; n = 34), or placebo (n = 39). Subjects met
<italic>DSM-IV</italic>
criteria for a depressive disorder, or operationally defined subsyndromal depression, and scored >12 on the first 17 items of the Hamilton Rating Scale for Depression (HAM-D). Subjects were followed for 12 weeks (6-week dosage adjustment, 6-week maintenance). Maximum daily dosages were 40 mg for paroxetine and 225 mg for venlafaxine XR. The primary outcome measure was change in the HAM-D score from baseline to week 12.</p>
</sec>
<sec>
<title>Results:</title>
<p>Treatment effects (relative to placebo), expressed as mean 12-week reductions in HAM-D score, were 6.2 points (97.5% confidence interval [CI] 2.2 to 10.3,
<italic>p</italic>
= 0.0007) in the paroxetine group and 4.2 points (97.5% CI 0.1 to 8.4,
<italic>p</italic>
= 0.02) in the venlafaxine XR group. No treatment effects were seen on motor function.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Both paroxetine and venlafaxine XR significantly improved depression in subjects with PD. Both medications were generally safe and well tolerated and did not worsen motor function.</p>
</sec>
<sec>
<title>Classification of Evidence:</title>
<p>This study provides Class I evidence that paroxetine and venlafaxine XR are effective in treating depression in patients with PD.</p>
</sec>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001119 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001119 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:3324323
   |texte=   A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:22496199" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022